{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:37:21Z","timestamp":1781548641817,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ypmed.2022.107237","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T19:28:34Z","timestamp":1661974114000},"page":"107237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain)"],"prefix":"10.1016","volume":"163","author":[{"given":"Pablo","family":"Chico-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gras-Valent\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Algado-Sell\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Jim\u00e9nez-Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermelinda","family":"Vanaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Peir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier S.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez-Pay\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ypmed.2022.107237_bb0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/vaccines9101143","article-title":"BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection and symptomatic disease in five-month follow-up: a retrospective cohort study","volume":"9","author":"Bianchi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ypmed.2022.107237_bb0020","article-title":"Effectiveness of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel","author":"Chico-S\u00e1nchez","year":"2022","journal-title":"Gac. Sanit."},{"key":"10.1016\/j.ypmed.2022.107237_bb0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0030","author":"DECRETO 10\/2021, de 16 de marzo, del President de la Generalitat por el que se crea el Comit\u00e9 Cient\u00edfico del Programa Valenciano de Investigaci\u00f3n Vacunal COVID-19 (ProVaVac)"},{"key":"10.1016\/j.ypmed.2022.107237_bb0035","author":"Estrategia de vacunaci\u00f3n COVID-19 en Espa\u00f1a l\u00edneas maestras"},{"key":"10.1016\/j.ypmed.2022.107237_bb0040","author":"Estrategia de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a"},{"key":"10.1016\/j.ypmed.2022.107237_bb0045","series-title":"Overview of COVID-19 Vaccination Strategies and Vaccine Deployment Plans in the EU\/EEA and the UK \u2013 2 December 2020","author":"European Centre for Disease Prevention and Control","year":"2020"},{"key":"10.1016\/j.ypmed.2022.107237_bb0050","series-title":"Enhanced Post-Marketing Monitoring of COVID-19 Vaccines in Europe","author":"European Centre for Disease Prevention and Control","year":"2021"},{"key":"10.1016\/j.ypmed.2022.107237_bb0055","series-title":"Interim Analysis of COVID-19 Vaccine Effectiveness against Severe Acute Respiratory Infection Due to Laboratory-Confirmed SARS-CoV-2 among Individuals Aged 50 Years and Older, ECDC Multi-Country Study \u2013 First Update","author":"European Centre for Disease Prevention and Control","year":"2022"},{"key":"10.1016\/j.ypmed.2022.107237_bb0060","series-title":"COVID-19 Vaccination and Prioritisation Strategies in the EU\/EEA. 22 December 2020","author":"European Centre for Disease Prevention and Control","year":"2020"},{"key":"10.1016\/j.ypmed.2022.107237_bb0065","first-page":"376","article-title":"Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study","author":"Fabiani","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2022.107237_bb0070","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/j.vaccine.2013.04.026","article-title":"The case test-negative design for studies of the effectiveness of influenza vaccine","volume":"31","author":"Foppa","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2022.107237_bb0075","article-title":"Effectiveness of the first dose of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel","volume":"95","author":"Gras-Valent\u00ed","year":"2021","journal-title":"Rev. Esp. Salud P\u00fablica."},{"key":"10.1016\/j.ypmed.2022.107237_bb0080","author":"Gu\u00eda T\u00e9cnica COMIRNATY (Vacuna COVID-19 ARNm, Pfizer-BioNTech)"},{"key":"10.1016\/j.ypmed.2022.107237_bb0085","author":"Gu\u00eda T\u00e9cnica SPIKEVAX (Vacuna COVID-19 ARNm, Moderna)"},{"key":"10.1016\/j.ypmed.2022.107237_bb0090","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2022.107237_bb0095","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ypmed.2022.107237_bb0100","series-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University","author":"Johns Hopkins University Coronavirus Resource Center","year":"2020"},{"key":"10.1016\/j.ypmed.2022.107237_bb0105","article-title":"SARS-CoV-2 infection after vaccination in health Care Workers in California","author":"Keehner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.15585\/mmwr.mm7109e3","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2022.107237_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ypmed.2022.107237_bb0120","author":"Ministerio de Sanidad"},{"key":"10.1016\/j.ypmed.2022.107237_bb0125","first-page":"ciab918","article-title":"Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study","author":"Muhsen","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ypmed.2022.107237_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm7020e2","article-title":"Interim estimates of vaccine effectiveness of Pfizer-BioNTech and moderna COVID-19 vaccines among health care personnel - 33 U.S. Sites, January\u2013March 2021","volume":"70","author":"Pilishvili","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2022.107237_bb0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0140","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2022.107237_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhin.2021.03.016","article-title":"Rapid decrease of SARS-CoV-2 circulation in a large Italian hospital six weeks after the start of the immunization program","volume":"112","author":"Stefanizzi","year":"2021","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.ypmed.2022.107237_bb0150","article-title":"Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel","author":"Swift","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ypmed.2022.107237_bb0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2022.107237_bb0160","series-title":"Evaluation of COVID-19 Vaccine Effectiveness. Interim Guidance","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.ypmed.2022.107237_bb0165","series-title":"WHO Target Product Profiles for COVID-19 Vaccines","author":"World Health Organization","year":"2022"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743522002869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743522002869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:17:05Z","timestamp":1758795425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743522002869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"alternative-id":["S0091743522002869"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2022.107237","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain)","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2022.107237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107237"}}